科微学术

微生物学通报

益生菌在血糖调控中的作用
作者:

The role of probiotics in blood glucose regulation
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [138]
  • |
  • 相似文献 [20]
  • | | |
  • 文章评论
    摘要:

    随着经济及生活水平的提高,营养过剩导致营养代谢疾病中2型糖尿病(type 2 diabetes mellitus,T2DM)发生率骤增。患者血糖升高及并发症严重降低生活质量,增加经济负担。现行降糖药存在局限性和副作用,而益生菌具有安全、经济和有效等特点,并且能够降血糖和减轻并发症等。益生菌在糖尿病预防、治疗和重塑肠道微生态健康方面具有良好的应用前景,逐渐成为糖尿病防治的研究热点。虽然益生菌有望攻克糖尿病,但是调控血糖的机制需要更加深入的研究。本文综述了益生菌调控血糖的应用及机制研究、发展趋势与前景及挑战,为调控血糖微生态制剂的开发提供理论基础。

    Abstract:

    As the economic level and living standards are rising, the incidence of type 2 diabetes mellitus (T2DM), a nutritional metabolic disease caused by overnutrition, has increased sharply. The elevated blood glucose level and complications seriously affect the quality of life of the patients and bring economic burden to the family. The drug treatment of T2DM has limitations and side effects. Although T2DM is difficult to be cured, some new therapies for regulating blood glucose have emerged with the deepening of research. Probiotics are safe, economical, and effective, and recent studies have shown that probiotics used alone or in combination with other therapies can lower blood glucose level and alleviate complications. Demonstrating a promising application prospect in the prevention and treatment of T2DM and the remodeling of intestinal microbiota, probiotics have become a hot research spot. While probiotics have the potential to overcome T2DM, the mechanism of probiotics in regulating blood glucose remain to be deciphered. This article reviews the role, application, prospect, and challenges of probiotics in blood glucose regulation, aiming to provide a theoretical basis for the development of microecological agents for blood glucose regulation in humans and companion animals.

    参考文献
    [1] RUZE R, LIU T, ZOU X, SONG J, CHEN Y, XU R, YIN X, XU Q. Obesity and type 2 diabetes mellitus:connections in epidemiology, pathogenesis, and treatments[J]. Frontiers in Endocrinology (Lausanne), 2023, 14:1161521.
    [2] MAJETY P, LOZADA ORQUERA FA, EDEM D, HAMDY O. Pharmacological approaches to the prevention of type 2 diabetes mellitus[J]. Frontiers in Endocrinology (Lausanne), 2023, 14:1118848.
    [3] SAEEDI P, PETERSOHN I, SALPEA P, MALANDA B, KARURANGA S, UNWIN N, COLAGIURI S, GUARIGUATA L, MOTALA AA, OGURTSOVA K, SHAW JE, BRIGHT D, WILLIAMS R, DIABETES ATLAS COMMITTEE IF. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:results from the International Diabetes Federation Diabetes Atlas, 9th edition[J]. Diabetes Research and Clinical Practice, 2019, 157:107843.
    [4] DAI M, GUO W, ZHU S, GONG G, CHEN M, ZHONG Z, GUO J, ZHANG Y. Type 2 diabetes mellitus and the risk of abnormal spermatozoa:a mendelian randomization study[J]. Front Endocrinol (Lausanne), 2022, 13:1035338.
    [5] WHANG A, NAGPAL R, YADAV H. Bi-directional drug-microbiome interactions of anti-diabetics[J]. EBioMedicine, 2019, 39:591-602.
    [6] NDJABOUE R, FARHAT I, FERLATTE CA, NGUETA G, GUAY D, DELORME S, IVERS N, SHAH BR, STRAUS S, YU C, WITTEMAN HO. Predictive models of diabetes complications:protocol for a scoping review[J]. Systematic Reviews, 2020, 9(1):1-14.
    [7] World Health Organization. (-2020)-. WHO package of essential noncommunicable (-PEN)-disease interventions for primary health care. World Health Organization. https://apps.who.int/iris/handle/10665/334186.
    [8] ASCHNER P. Insulin therapy in type 2 diabetes[J]. American Journal of Therapeutics, 2020, 27(1):e79-e90.
    [9] GAN S, DAWED A, DONNELLY L, NAIR A, PALMER C, MOHAN V, PEARSON E. Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and Asian patients with diabetes:a systematic review and meta-analysis of randomized controlled trials[J]. Diabetes Care, 2020, 43(8):1948-1957.
    [10] JADZINSKY M, PFÜTZNER A, PAZ-PACHECO E, XU Z, ALLEN E, CHEN R, INVESTIGATORS C. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy:a randomized controlled trial[J]. Diabetes, Obesity and Metabolism, 2009, 11(6):611-622.
    [11] MONAMI M, VITALE V, AMBROSIO ML, BARTOLI N, TOFFANELLO G, RAGGHIANTI B, MONAMI F, MARCHIONNI N, MANNUCCI E. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas:meta-analysis of placebo-controlled trials[J]. Advances in Therapy, 2012, 29(9):736-746.
    [12] LEE J. The microbiome and gut homeostasis[J]. Sichuan Journal of Physiological Sciences, 2022, 44(6):1092.
    [13] EJTAHED HS, MOHTADI-NIA J, HOMAYOUNI-RAD A, NIAFAR M, ASGHARI-JAFARABADI M, MOFID V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients[J]. Nutrition, 2012, 28(5):539-543.
    [14] SHARIFI-RAD J, RODRIGUES CF, STOJANOVIĆ-RADIĆ Z, DIMITRIJEVIĆ M, ALEKSIĆ A, NEFFE-SKOCIŃSKA K, ZIELIŃSKA D, KOŁOŻYN-KRAJEWSKA D, SALEHI B, MILTON PRABU S, SCHUTZ F, DOCEA AO, MARTINS N, CALINA D. Probiotics:versatile bioactive components in promoting human health[J]. Medicina, 2020, 56(9):433.
    [15] YADAV MK, KUMARI I, SINGH B, SHARMA KK, TIWARI SK. Probiotics, prebiotics and synbiotics:safe options for next-generation therapeutics[J]. Applied Microbiology and Biotechnology, 2022, 106(2):505-521.
    [16] HARANAHALLI NATARAJ B, NAITHANI H, NAGPAL R, BEHARE PV. Bacteriocins and antimicrobial peptides as an alternative to antibiotics[M]//Advances in Dairy Microbial Products. Amsterdam:Elsevier, 2022:327-346.
    [17] SOLTANI S, HAMMAMI R, COTTER PD, REBUFFAT S, BEN SAID L, GAUDREAU H, BÉDARD F, BIRON E, DRIDER D, FLISS I. Bacteriocins as a new generation of antimicrobials:toxicity aspects and regulations[J]. FEMS Microbiology Reviews, 2021, 45(1):fuaa039.
    [18] 吕文亮, 张甜甜, 林显华, 鹿瑶, 徐海燕, 谷巍. 植物乳杆菌防治鸡白痢沙门菌感染的效果评价[J]. 中国饲料, 2022(11):75-80. LÜ WL, ZHANG TT, LIN XH, LU Y, XU HY, GU W. Effect evaluation of Lactobacillus plantarum on Salmonella pullorum infection in chickens[J]. China Feed, 2022(11):75-80(in Chinese).
    [19] PENG XQ, ED-DRA A, SONG Y, ELBEDIWI M, NAMBIAR RB, ZHOU X, YUE M. Lacticaseibacillus rhamnosus alleviates intestinal inflammation and promotes microbiota-mediated protection against Salmonella fatal infections[J]. Frontiers in Immunology, 2022, 13:973224.
    [20] SMITH D, JHEETA S, FUENTES HV, PALACIOS-PÉREZ M. Feeding our microbiota:stimulation of the immune/semiochemical system and the potential amelioration of non-communicable diseases[J]. Life, 2022, 12(8):1197.
    [21] GLAZUNOVA OA, MOISEENKO KV, SAVINOVA OS, FEDOROVA TV. In vitro and in vivo antihypertensive effect of milk fermented with different strains of common starter lactic acid bacteria[J]. Nutrients, 2022, 14(24):5357.
    [22] YANG Y, ZHAO S, YANG X, LI W, SI J, YAMG X. The antidepressant potential of Lactobacillus casei in the postpartum depression rat model mediated by the microbiota-gut-brain axis[J]. Neuroscience Letters, 2022, 774:136474.
    [23] ZHOU J, LI MY, CHEN QF, LI XJ, CHEN LF, DONG ZL, ZHU WJ, YANG Y, LIU Z, CHEN Q. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery[J]. Nature Communications, 2022, 13:3432.
    [24] LI G, FENG H, MAO XL, DENG YJ, WANG XB, ZHANG Q, GUO Y, XIAO SM. The effects of probiotics supplementation on glycaemic control among adults with type 2 diabetes mellitus:a systematic review and meta-analysis of randomised clinical trials[J]. Journal of Translational Medicine, 2023, 21(1):1-16.
    [25] PAUL P, KAUL R, HARFOUCHE M, ARABI M, AL-NAJJAR Y, SARKAR A, SALIBA R, CHAARI A. The effect of microbiome-modulating probiotics, prebiotics and synbiotics on glucose homeostasis in type 2 diabetes:a systematic review, meta-analysis, and meta-regression of clinical trials[J]. Pharmacological Research, 2022, 185:106520.
    [26] TOEJING P, KHAMPITHUM N, SIRILUN S, CHAIYASUT C, LAILERD N. Influence of Lactobacillus paracasei HII01 supplementation on glycemia and inflammatory biomarkers in type 2 diabetes:a randomized clinical trial[J]. Foods, 2021, 10(7):1455.
    [27] MIRMIRANPOUR H, HUSEINI HF, DERAKHSHANIAN H, KHODAII Z, TAVAKOLI-FAR B. Effects of probiotic, cinnamon, and synbiotic supplementation on glycemic control and antioxidant status in people with type 2 diabetes; a randomized, double-blind, placebo-controlled study[J]. Journal of Diabetes and Metabolic Disorders, 2020, 19(1):53-60.
    [28] VELAYATI A, KAREEM I, SEDAGHAT M, SOHRAB G, NIKPAYAM O, HEDAYATI M, ABHARI K, HEJAZI E. Does symbiotic supplementation which contains Bacillus Coagulans Lactobacillus rhamnosus, Lactobacillus acidophilusand fructooligosaccharide has favourite effects in patients with type-2 diabetes? A randomised, double-blind, placebo-controlled trial[J]. Archives of Physiology and Biochemistry, 2021:1-8.
    [29] CHAIYASUT C, SIVAMARUTHI BS, LAILERD N, SIRILUN S, THANGALEELA S, KHONGTAN S, BHARATHI M, KESIKA P, SAELEE M, CHOEISOONGNERN T, FUKNGOEN P, PEERAJAN S, SITTIPRAPAPORN P. Influence of Bifidobacterium breve on the glycaemic control, lipid profile and microbiome of type 2 diabetic subjects:a preliminary randomized clinical trial[J]. Pharmaceuticals, 2023, 16(5):695.
    [30] GU YX, CHEN HR, LI X, LI D, SUN Y, YANG L, MA Y, CHAN ECY. Lactobacillus paracasei IMC 502 ameliorates type 2 diabetes by mediating gut microbiota-SCFA-hormone/inflammation pathway in mice[J]. Journal of the Science of Food and Agriculture, 2023, 103(6):2949-2959.
    [31] TOEJING P, KHAT-UDOMKIRI N, INTAKHAD J, SIRILUN S, CHAIYASUT C, LAILERD N. Putative mechanisms responsible for the antihyperglycemic action of Lactobacillus paracasei HII01 in experimental type 2 diabetic rats[J]. Nutrients, 2020, 12(10):3015.
    [32] ROGLIĆ G. WHO Global report on diabetes:a summary[J]. International Journal of Noncommunicable Diseases, 2016, 1:3-8.
    [33] CHENG AYY, GOMES MB, KALRA S, KENGNE AP, MATHIEU C, SHAW JE. Applying the WHO global targets for diabetes mellitus[J]. Nature Reviews Endocrinology, 2023, 19(4):194-200.
    [34] GREGG EW, BUCKLEY J, ALI MK, DAVIES J, FLOOD D, MEHTA R, GRIFFITHS B, LIM LL, MANNE-GOEHLER J, PEARSON-STUTTARD J, TANDON N, ROGLIC G, SLAMA S, SHAW JE. Improving health outcomes of people with diabetes:target setting for the WHO global diabetes compact[J]. Lancet, 2023401(10384):1302-1312.
    [35] CAMPBELL MR, SHOKRANI M. Introduction, background and various types[J]. American Society for Clinical Laboratory Science, 2016, 29(2):106-110.
    [36] MP D, SHARMA R, RIAZ I, SUDHANSHU S, PARIKH R, BHATIA V. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016:a pooled analysis of 2416 population-based measurement studies in 128. 9 million children, adolescents and adults[J]. Yearbook of Paediatric Endocrinology, 2017, 390(10113):2627-2642.
    [37] SANYAL D. Diabetes is predominantly an intestinal disease[J]. Indian Journal of Endocrinology and Metabolism, 2013, 17(supplement 1):S64-S67.
    [38] RUBIO-NAVARRO A, GÓMEZ-BANOY N, STOLL L, DÜNDAR F, MAWLA AM, MA LK, CORTADA E, ZUMBO P, LI A, REITERER M, MONTOYA-OVIEDO N, HOMAN EA, IMAI N, GILANI A, LIU CY, NAJI AL, YANG B, CHONG ACN, COHEN DE, CHEN SB, et al. A beta cell subset with enhanced insulin secretion and glucose metabolism is reduced in type 2 diabetes[J]. Nature Cell Biology, 2023, 25(4):565-578.
    [39] ZHANG YQ, HAN S, LIU CC, ZHENG YW, LI H, GAO F, BIAN YH, LIU X, LIU HB, HU SR, LI YX, CHEN ZJ, ZHAO SG, ZHAO H. THADA inhibition in mice protects against type 2 diabetes mellitus by improving pancreatic β-cell function and preserving β-cell mass[J]. Nature Communications, 2023, 14:1020.
    [40] 何嘉骐, 张静, 倪军. 肠道菌群与2型糖尿病的关系及研究进展[J]. 实用医药杂志, 2021, 38(3):277-280, 288. HE JQ, ZHANG J, NI J. The relationship between intestinal flora and type 2 diabetes mellitus and its research progress[J]. Practical Journal of Medicine & Pharmacy, 2021, 38(3):277-280, 288(in Chinese).
    [41] 阿荣, 张洁. 肠道菌群失调与糖尿病相关性的研究进展[J]. 中国当代医药, 2023, 30(13):43-49. A R, ZHANG J. Research progress on the correlation between gut microbiota disorder and diabetes mellitus[J]. China Modern Medicine, 2023, 30(13):43-49(in Chinese).
    [42] SCHEITHAUER TPM, RAMPANELLI E, NIEUWDORP M, VALLANCE BA, VERCHERE CB, van RAALTE DH, HERREMA H. Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes[J]. Frontiers in Immunology, 2020, 11:571731.
    [43] 蔡淑珍, 梁婷婷, 张菊梅, 陈惠元, 吴清平. 基于肠道微生态改善的益生菌抗糖尿病作用机制研究进展[J]. 微生物学报, 2023, 63(1):59-75. CAI SZ, LIANG TT, ZHANG JM, CHEN HY, WU QP. Anti-diabetes mechanism of probiotics based on intestinal microecology[J]. Acta Microbiologica Sinica, 2023, 63(1):59-75(in Chinese).
    [44] ZHOU YD, LIANG FX, TIAN HR, LUO D, WANG YY, YANG SR. Mechanisms of gut microbiota-immune-host interaction on glucose regulation in type 2 diabetes[J]. Frontiers in Microbiology, 2023, 14:1121695.
    [45] TOMIC D, SHAW JE, MAGLIANO DJ. The burden and risks of emerging complications of diabetes mellitus[J]. Nature Reviews Endocrinology, 2022, 18(9):525-539.
    [46] LIU G, LI YP, PAN A, HU Y, CHEN SY, QIAN F, RIMM EB, MANSON JE, STAMPFER MJ, GIATSIDIS G, SUN Q. Adherence to a healthy lifestyle in association with microvascular complications among adults with type 2 diabetes[J]. JAMA Network Open, 2023, 6(1):e2252239.
    [47] YAP J, ANBALAKAN K, TAY WT, TING D, CHEUNG CY, SABANAYAGAM C, CHENG CY, WONG TY, YEO KK. Impact of type 2 diabetes and microvascular complications on mortality and cardiovascular outcomes in a multiethnic Asian population[J]. BMJ Open Diabetes Research & Care, 2021, 9(1):e001413.
    [48] COLE JB, FLOREZ JC. Genetics of diabetes mellitus and diabetes complications[J]. Nature Reviews Nephrology, 2020, 16(7):377-390.
    [49] IKEDA S, SHINOHARA K, ENZAN N, MATSUSHIMA S, TOHYAMA T, FUNAKOSHI K, KISHIMOTO J, ITOH H, KOMURO I, TSUTSUI H. A higher resting heart rate is associated with cardiovascular event risk in patients with type 2 diabetes mellitus without known cardiovascular disease[J]. Hypertension Research:Official Journal of the Japanese Society of Hypertension, 2023, 46(5):1090-1099.
    [50] RASTOGI A, DUNBAR RL, THACKER HP, BHATT J, PARMAR K, PARMAR DV. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus:a randomized, placebo-controlled study[J]. Acta Diabetologica, 2020, 57(7):809-818.
    [51] ZINMAN B, BHOSEKAR V, BUSCH R, HOLST I, LUDVIK B, THIELKE D, THRASHER J, WOO V, PHILIS-TSIMIKAS A. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9):a randomised, placebo-controlled trial[J]. The Lancet Diabetes & Endocrinology, 2019, 7(5):356-367.
    [52] GUZMAN CB, ZHANG XM, LIU R, REGEV A, SHANKAR S, GARHYAN P, PILLAI SG, KAZDA C, CHALASANI N, HARDY TA. Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes[J]. Diabetes, Obesity and Metabolism, 2017, 19(11):1521-1528.
    [53] PINTARIČ M, LANGERHOLC T. Probiotic mechanisms affecting glucose homeostasis:a scoping review[J]. Life, 2022, 12(8):1187.
    [54] 唐曼玉, 王晚晴, 强敬雯, 华威, 武双, 李亚丽, 甄新, 李春庚, 程艳玲. 益生菌与肠道菌群、免疫调节的相互作用与机制研究进展[J]. 食品工业科技, 2022, 43(16):486-493. TANG MY, WANG WQ, QIANG JW, HUA W, WU S, LI YL, ZHEN X, LI CG, CHENG YL. Interaction and mechanism of probiotics with gut flora and immune regulation:a review[J]. Science and Technology of Food Industry, 2022, 43(16):486-493(in Chinese).
    [55] LIU DL, ZHANG SB, LI SJ, ZHANG Q, CAI Y, LI P, LI H, SHEN BC, LIAO QF, HONG YJ, XIE ZY. Indoleacrylic acid produced by Parabacteroides distasonis alleviates type 2 diabetes via activation of AhR to repair intestinal barrier[J]. BMC Biology, 2023, 21(1):90.
    [56] 鞠林. 益生菌作用机制研究进展[J]. 山东畜牧兽医, 2023, 44(4):79-80, 84. JU L. Research progress on the mechanism of probiotics[J]. Shandong Journal of Animal Science and Veterinary Medicine, 2023, 44(4):79-80, 84(in Chinese).
    [57] 杜伟, 叶邦策, 漆楠. 基于肠道微生物及其代谢产物的2型糖尿病治疗药物的研究进展[J]. 现代药物与临床, 2021, 36(1):191-196. DU W, YE BC, QI N. Research progress of drugs for the treatment of type 2 diabetes based on gut microbiome and microbial-derived metabolites[J]. Drugs & Clinic, 2021, 36(1):191-196(in Chinese).
    [58] LIU TC, KERN JT, JAIN U, SONNEK NM, XIONG SS, SIMPSON KF, van DUSSEN KL, WINKLER ES, HARITUNIANS T, MALIQUE A, LU QH, SASAKI Y, STORER C, DIAMOND MS, HEAD RD, MCGOVERN DPB, STAPPENBECK TS. Western diet induces Paneth cell defects through microbiome alterations and farnesoid X receptor and type I interferon activation[J]. Cell Host & Microbe, 2021, 29(6):988-1001.e6.
    [59] CARLOS D, PÉREZ MM, LEITE JA, ROCHA FA, MARTINS LMS, PEREIRA CA, FRAGA-SILVA TFC, PUCCI TA, RAMOS SG, CÂMARA NOS, BONATO VLD, TOSTES RC, SILVA JS. NOD2 deficiency promotes intestinal CD4+ T lymphocyte imbalance, metainflammation, and aggravates type 2 diabetes in murine model[J]. Frontiers in Immunology, 2020, 11:1265.
    [60] 吴峥嵘. 益生菌防治糖尿病的研究进展[J]. 北方药学, 2021, 18(3):188-190. WU ZR. Research progress of probiotics in preventing and treating diabetes mellitus[J]. Journal of North Pharmacy, 2021, 18(3):188-190(in Chinese).
    [61] MIRAGHAJANI M, DEHSOUKHTEH SS, RAFIE N, HAMEDANI SG, SABIHI S, GHIASVAND R. Potential mechanisms linking probiotics to diabetes:a narrative review of the literature[J]. Sao Paulo Medical Journal, 2017, 135(2):169-178.
    [62] GABANYI I, LEPOUSEZ G, WHEELER R, VIEITES-PRADO A, NISSANT A, CHEVALIER G, WAGNER S, MOIGNEU C, DULAUROY S, HICHAM S, POLOMACK B, VERNY F, ROSENSTIEL P, RENIER N, BONECA IG, EBERL G, LLEDO PM. Bacterial sensing via neuronal Nod2 regulates appetite and body temperature[J]. Science, 2022, 376(6590):eabj3986.
    [63] 蒋岚, 陈果, 高陈林, 徐勇. 益生菌对T2DM患者肠道菌群和脂联素的影响[J]. 中国现代医学杂志, 2018, 28(11):84-87. JIANG L, CHEN G, GAO CL, XU Y. Curative efficacy of probiotics on intestinal microflora and adiponectin in patients with type 2 diabetes mellitus[J]. China Journal of Modern Medicine, 2018, 28(11):84-87(in Chinese).
    [64] NOORMOHAMMADI M, GHORBANI Z, LÖBER U, MAHDAVI-ROSHAN M, BARTOLOMAEUS TUP, KAZEMI A, SHOAIBINOBARIAN N, FORSLUND SK. The effect of probiotic and synbiotic supplementation on appetite-regulating hormones and desire to eat:a systematic review and meta-analysis of clinical trials[J]. Pharmacological Research, 2023, 187:106614.
    [65] KADOWAKI T. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome[J]. Journal of Clinical Investigation, 2006, 116(7):1784-1792.
    [66] RUAN H. Adiponectin signaling and function in insulin target tissues[J]. Journal of Molecular Cell Biology, 2016, 8(2):101-109.
    [67] YANAI H, YOSHIDA H. Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression:mechanisms and perspectives[J]. International Journal of Molecular Sciences, 2019, 20(5):1190.
    [68] ACHARI AE, JAIN SK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction[J]. International Journal of Molecular Sciences, 2017, 18(6):1321.
    [69] LIU D, WU L, GAO QM, LONG XX, HOU XH, QIAN LL, NI JC, FANG QC, LI HT, JIA WP. FGF21/adiponectin ratio predicts deterioration in glycemia:a 4.6-year prospective study in China[J]. Cardiovascular Diabetology, 2021, 20(1):157.
    [70] GUO Q, CAO SC, WANG XH. Adiponectin intervention to regulate betatrophin expression, attenuate insulin resistance and enhance glucose metabolism in mice and its response to exercise[J]. International Journal of Molecular Sciences, 2022, 23(18):10630.
    [71] WANG YM, DILIDAXI D, WU Y, SAILIKE J, SUN X, NABI XH. Composite probiotics alleviate type 2 diabetes by regulating intestinal microbiota and inducing GLP-1 secretion in db/db mice[J]. Biomedicine & Pharmacotherapy, 2020, 125:109914.
    [72] HAN X, WANG Y, ZHANG PP, ZHU ML, LI L, MAO XM, SHA XT, LI LL. Kazak faecal microbiota transplantation induces short-chain fatty acids that promote glucagon-like peptide-1 secretion by regulating gut microbiota in db/db mice[J]. Pharmaceutical Biology, 2021, 59(1):1075-1085.
    [73] ZHAO JY, WANG LH, CHENG SS, ZHANG Y, YANG M, FANG RX, LI HX, MAN CX, JIANG YJ. A potential synbiotic strategy for the prevention of type 2 diabetes:Lactobacillus paracasei JY062 and exopolysaccharide isolated from Lactobacillus plantarum JY039[J]. Nutrients, 2022, 14(2):377.
    [74] XIAO R, WANG LL, TIAN PJ, JIN X, ZHAO JX, ZHANG H, WANG G, ZHU MM. The effect of probiotic supplementation on glucolipid metabolism in patients with type 2 diabetes:a systematic review and meta-analysis[J]. Nutrients, 2023, 15(14):3240.
    [75] 梁磊, 念馨. 肠道菌群:未来2型糖尿病治疗的新靶点[J]. 实用医学杂志, 2022, 38(3):261-265. LIANG L, NIAN X. Intestinal microbiota:a new target for treatment of type 2 diabetes in future[J]. The Journal of Practical Medicine, 2022, 38(3):261-265(in Chinese).
    [76] PLAZA-DIAZ J, RUIZ-OJEDA FJ, GIL-CAMPOS M, GIL A. Mechanisms of action of probiotics[J]. Advances in Nutrition (Bethesda, Md), 2019, 10(suppl_1):S49-S66.
    [77] NIIBO M, SHIROUCHI B, UMEGATANI M, MORITA Y, OGAWA A, SAKAI F, KADOOKA Y, SATO M. Probiotic Lactobacillus gasseri SBT2055 improves insulin secretion in a diabetic rat model[J]. Journal of Dairy Science, 2019, 102(2):997-1006.
    [78] KOCSIS T, MOLNÁR B, NÉMETH D, HEGYI P, SZAKÁCS Z, BÁLINT A, GARAMI A, SOÓS A, MÁRTA K, SOLYMÁR M. Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus:a meta-analysis of randomized clinical trials[J]. Scientific Reports, 2020, 10:11787.
    [79] KHALILI L, ALIPOUR B, ASGHARI JAFAR-ABADI M, FARAJI I, HASSANALILOU T, MESGARI ABBASI M, VAGHEF-MEHRABANY E, ALIZADEH SANI M. The effects of Lactobacillus casei on glycemic response, serum Sirtuin1 and fetuin-a levels in patients with type 2 diabetes mellitus:a randomized controlled trial[J]. Iranian Biomedical Journal, 2019, 23(1):68-77.
    [80] RAZMPOOSH E, JAVADI A, EJTAHED HS, MIRMIRAN P, JAVADI M, YOUSEFINEJAD A. The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes:a randomized placebo controlled trial[J]. Diabetes & Metabolic Syndrome:Clinical Research & Reviews, 2019, 13(1):175-182.
    [81] MANAER T, YU L, NABI XH, DILIDAXI D, LIU L, SAILIKE J. The beneficial effects of the composite probiotics from camel milk on glucose and lipid metabolism, liver and renal function and gut microbiota in db/db mice[J]. BMC Complementary Medicine and Therapies, 2021, 21(1):1-13.
    [82] NASERI K, SAADATI S, GHAEMI F, ASHTARY-LARKY D, ASBAGHI O, SADEGHI A, AFRISHAM R, COURTEN B. The effects of probiotic and synbiotic supplementation on inflammation, oxidative stress, and circulating adiponectin and leptin concentration in subjects with prediabetes and type 2 diabetes mellitus:a GRADE-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials[J]. European Journal of Nutrition, 2023, 62(2):543-561.
    [83] MARKOWIAK-KOPEĆ P, ŚLIŻEWSKA K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome[J]. Nutrients, 2020, 12(4):1107.
    [84] WANG CH, YEN HR, LU WL, HO HH, LIN WY, KUO YW, HUANG yen-yu, TSAI SY, LIN HC. Adjuvant probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 attenuate glycemic levels and inflammatory cytokines in patients with type 1 diabetes mellitus[J]. Frontiers in Endocrinology, 2022, 13:754401.
    [85] ZENG Z, GUO XX, ZHANG JL, YUAN QP, CHEN SW. Lactobacillus paracasei modulates the gut microbiota and improves inflammation in type 2 diabetic rats[J]. Food & Function, 2021, 12(15):6809-6820.
    [86] GENTILE CL, WEIR TL. The gut microbiota at the intersection of diet and human health[J]. Science, 2018, 362(6416):776-780.
    [87] MA QT, LI YQ, LI PF, WANG M, WANG JK, TANG ZY, WANG T, LUO LL, WANG CG, WANG T, ZHAO BS. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora[J]. Biomedicine & Pharmacotherapy, 2019, 117:109138.
    [88] JIANG HR, CAI MM, SHEN BY, WANG Q, ZHANG TC, ZHOU X. Synbiotics and gut microbiota:new perspectives in the treatment of type 2 diabetes mellitus[J]. Foods, 2022, 11(16):2438.
    [89] CABELLO-OLMO M, ONECA M, PAJARES MJ, JIMÉNEZ M, AYO J, ENCÍO IJ, BARAJAS M, ARAÑA M. Antidiabetic effects of Pediococcus acidilactici pA1c on HFD-induced mice[J]. Nutrients, 2022, 14(3):692.
    [90] LIU Y, ZHENG SJ, CUI JL, GUO TT, ZHANG JT. Lactiplantibacillus plantarum Y15 alleviate type 2 diabetes in mice via modulating gut microbiota and regulating NF-κB and insulin signaling pathway[J]. Brazilian Journal of Microbiology, 2022, 53(2):935-945.
    [91] ARCHER AC, MUTHUKUMAR SP, HALAMI PM. Lactobacillus fermentum MCC2759 and MCC2760 alleviate inflammation and intestinal function in high-fat diet-fed and streptozotocin-induced diabetic rats[J]. Probiotics and Antimicrobial Proteins, 2021, 13(4):1068-1080.
    [92] LEE YS, LEE D, PARK GS, KO SH, PARK J, LEE YK, KANG J. Lactobacillus plantarum HAC01 ameliorates type 2 diabetes in high-fat diet and streptozotocin-induced diabetic mice in association with modulating the gut microbiota[J]. Food & Function, 2021, 12(14):6363-6373.
    [93] GULNAZ A, NADEEM J, HAN JH, LEW LC, SON JD, PARK YH, RATHER IA, HOR YY. Lactobacillus sps in reducing the risk of diabetes in high-fat diet-induced diabetic mice by modulating the gut microbiome and inhibiting key digestive enzymes associated with diabetes[J]. Biology, 2021, 10(4):348.
    [94] RODRIGUES RR, GURUNG M, LI ZP, GARCÍA-JARAMILLO M, GREER R, GAULKE C, BAUCHINGER F, YOU H, PEDERSON JW, VASQUEZ-PEREZ S, WHITE KD, FRINK B, PHILMUS B, JUMP DB, TRINCHIERI G, BERRY D, SHARPTON TJ, DZUTSEV A, MORGUN A, SHULZHENKO N. TransKingdom interactions between Lactobacilli and hepatic mitochondria attenuate western diet-induced diabetes[J]. Nature Communications, 2021, 12:101.
    [95] KOAY KP, TSAI BCK, KUO CH, KUO WW, LUK HN, DAY CH, CHEN RJ, CHEN MYC, PADMA VV, HUANG CY. Hyperglycemia-induced cardiac damage is alleviated by heat-inactivated Lactobacillus reuteri GMNL-263 via activation of the IGF1R survival pathway[J]. Probiotics and Antimicrobial Proteins, 2021, 13(4):1044-1053.
    [96] ZHOU XR, SHANG GS, TAN Q, HE Q, TAN XY, PARK KY, ZHAO X. Effect of Lactobacillus fermentum TKSN041 on improving streptozotocin-induced type 2 diabetes in rats[J]. Food & Function, 2021, 12(17):7938-7953.
    [97] TONUCCI LB, OLBRICH dos SANTOS KM, LICURSI de OLIVEIRA L, ROCHA RIBEIRO SM, DUARTE MARTINO HS. Clinical application of probiotics in type 2 diabetes mellitus:a randomized, double-blind, placebo-controlled study[J]. Clinical Nutrition (Edinburgh, Scotland), 2017, 36(1):85-92.
    [98] EBRAHIMI ZS, NASLI-ESFAHANI E, NADJARZADE A, MOZAFFARI-KHOSRAVI H. Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes:a randomized, double-blind, clinical trial[J]. Journal of Diabetes & Metabolic Disorders, 2017, 16(1):23.
    [99] SOLEIMANI A, MOTAMEDZADEH A, MOJARRAD MZ, BAHMANI F, AMIRANI E, OSTADMOHAMMADI V, TAJABADI-EBRAHIMI M, ASEMI Z. The effects of synbiotic supplementation on metabolic status in diabetic patients undergoing hemodialysis:a randomized, double-blinded, placebo-controlled trial[J]. Probiotics and Antimicrobial Proteins, 2019, 11(4):1248-1256.
    [100] LI HY, ZHOU DD, GAN RY, HUANG SY, ZHAO CN, SHANG A, XU XY, LI HB. Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota:a narrative review[J]. Nutrients, 2021, 13(9):3211.
    [101] KVAKOVA M, BERTKOVA I, STOFILOVA J, SAVIDGE TC. Co-encapsulated synbiotics and immobilized probiotics in human health and gut microbiota modulation[J]. Foods, 2021, 10(6):1297.
    [102] ZEPEDA-HERNÁNDEZ A, GARCIA-AMEZQUITA LE, REQUENA T, GARCÍA-CAYUELA T. Probiotics, prebiotics, and synbiotics added to dairy products:uses and applications to manage type 2 diabetes[J]. Food Research International, 2021, 142:110208.
    [103] SALMINEN S, COLLADO MC, ENDO A, HILL C, LEBEER S, QUIGLEY EMM, ELLEN SANDERS M, SHAMIR R, SWANN JR, SZAJEWSKA H, VINDEROLA G. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics[J]. Nature Reviews Gastroenterology & Hepatology, 2021, 18(9):649-667.
    [104] SCOTT E, de PAEPE K, van de WIELE T. Postbiotics and their health modulatory biomolecules[J]. Biomolecules, 2022, 12(11):1640.
    [105] HERNÁNDEZ MAG, CANFORA EE, JOCKEN JWE, BLAAK EE. The short-chain fatty acid acetate in body weight control and insulin sensitivity[J]. Nutrients, 2019, 11(8):1943.
    [106] MANDALIYA DK, PATEL S, SESHADRI S. The combinatorial effect of acetate and propionate on high-fat diet induced diabetic inflammation or metaflammation and T cell polarization[J]. Inflammation, 2021, 44(1):68-79.
    [107] WILLIAMS L, ALSHEHRI A, ROBICHAUD B, CUDMORE A, GAGNON J. The role of the bacterial muramyl dipeptide in the regulation of GLP-1 and glycemia[J]. International Journal of Molecular Sciences, 2020, 21(15):5252.
    [108] PLOVIER H, EVERARD A, DRUART C, DEPOMMIER C, van HUL M, GEURTS L, CHILLOUX J, OTTMAN N, DUPARC T, LICHTENSTEIN L, MYRIDAKIS A, DELZENNE NM, KLIEVINK J, BHATTACHARJEE A, van der ARK KCH, AALVINK S, MARTINEZ LO, DUMAS ME, MAITER D, LOUMAYE A, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice[J]. Nature Medicine, 2017, 23(1):107-113.
    [109] PARK M, JOUNG M, PARK JH, HA SK, PARK HY. Role of postbiotics in diet-induced metabolic disorders[J]. Nutrients, 2022, 14(18):3701.
    [110] da SILVA TF, CASAROTTI SN, LELIS VILELA de OLIVEIRA G, PENNA ALB. The impact of probiotics, prebiotics, and synbiotics on the biochemical, clinical, and immunological markers, as well as on the gut microbiota of obese hosts[J]. Critical Reviews in Food Science and Nutrition, 2021, 61(2):337-355.
    [111] WU JY, WANG K, WANG XM, PANG YL, JIANG CT. The role of the gut microbiome and its metabolites in metabolic diseases[J]. Protein & Cell, 2021, 12(5):360-373.
    [112] DUAN FF, LIU JH, MARCH JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes[J]. Diabetes, 2015, 64(5):1794-1803.
    [113] LUO J, ZHANG HF, LU JC, MA CL, CHEN TT. Antidiabetic effect of an engineered bacterium Lactobacillus plantarum-pMG36e-GLP-1 in monkey model[J]. Synthetic and Systems Biotechnology, 2021, 6:272-282.
    [114] ZHANG XY, MA N, LING W, PANG GJ, SUN T, LIU J, PAN HZ, CUI MH, HAN CL, YANG C, CHANG J, HUANG X, WANG HJ. A micro-nano optogenetic system based on probiotics for in situ host metabolism regulation[J]. Nano Research, 2023, 16(2):2829-2839.
    [115] 陈晔, 王彦杰, 尤利军, 靳昊, 张丹, 李冬梅, 张和平. 益生菌Probio-Fit联合二甲双胍对Ⅱ型糖尿病患者疗效及肠道菌群结构的影响[J]. 中国食品学报, 2019, 19(4):16-26. CHEN Y, WANG YJ, YOU LJ, JIN H, ZHANG D, LI DM, ZHANG HP. Effect of combination treatment with metformin and probiotics probio-fit (R) on clinical symptoms and gut microbiota structure in type 2 diabetes[J]. Journal of Chinese Institute of Food Science and Technology, 2019, 19(4):16-26(in Chinese).
    [116] ZHANG W, JIA XZ, XU YH, XIE QL, ZHU MZ, ZHANG HS, ZHAO ZF, HAO JY, LI HQ, DU JR, LIU Y, LIU WH, MA X, HUNG W, FENG HT, LI HW. Effects of Coix seed extract, Bifidobacterium BPL1, and their combination on the glycolipid metabolism in obese mice[J]. Frontiers in Nutrition, 2022, 9:939423.
    [117] JANG SH, PARK J, KIM SH, CHOI KM, KO ES, CHA JD, LEE YR, JANG H, JANG YS. Red ginseng powder fermented with probiotics exerts antidiabetic effects in the streptozotocin-induced mouse diabetes model[J]. Pharmaceutical Biology, 2017, 55(1):317-323.
    [118] SIONEK B, SZYDŁOWSKA A, ZIELIŃSKA D, NEFFE-SKOCIŃSKA K, KOŁOŻYN-KRAJEWSKA D. Beneficial bacteria isolated from food in relation to the next generation of probiotics[J]. Microorganisms, 2023, 11(7):1714.
    [119] VALLIANOU NG, KOUNATIDIS D, TSILINGIRIS D, PANAGOPOULOS F, CHRISTODOULATOS GS, EVANGELOPOULOS A, KARAMPELA I, DALAMAGA M. The role of next-generation probiotics in obesity and obesity-associated disorders:current knowledge and future perspectives[J]. International Journal of Molecular Sciences, 2023, 24(7):6755.
    [120] KOBYLIAK N, FALALYEYEVA T, KYRIACHENKO Y, TSEYSLYER Y, KOVALCHUK O, HADILIIA O, ESLAMI M, YOUSEFI B, ABENAVOLI L, FAGOONEE S, PELLICANO R. Akkermansia muciniphila as a novel powerful bacterial player in the treatment of metabolic disorders[J]. Minerva Endocrinology, 2022, 47(2):242-252.
    [121] 贺凯茹, 乌日娜, 丁瑞雪, 纪帅奇, 朱永亮, 武俊瑞. 下一代益生菌Akk菌的研究进展[J]. 微生物学通报, 2022, 49(6):2308-2324. HE KR, WU RN, DING RX, JI SQ, ZHU YL, WU JR. Research progress of the next-generation probiotics Akkermansia muciniphila[J]. Microbiology China, 2022, 49(6):2308-2324(in Chinese).
    [122] JIAN HF, LIU YT, WANG XM, DONG XY, ZOU XT. Akkermansia muciniphila as a next-generation probiotic in modulating human metabolic homeostasis and disease progression:a role mediated by gut-liver-brain axes?[J]. International Journal of Molecular Sciences, 2023, 24(4):3900.
    [123] DEPOMMIER C, van HUL M, EVERARD A, DELZENNE NM, de VOS WM, CANI PD. Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice[J]. Gut Microbes, 2020, 11(5):1231-1245.
    [124] EVERARD A, PLOVIER H, RASTELLI M, van HUL M, de WOUTERS D'OPLINTER A, GEURTS L, DRUART C, ROBINE S, DELZENNE NM, MUCCIOLI GG, de VOS WM, LUQUET S, FLAMAND N, Di MARZO V, CANI PD. Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis[J]. Nature Communications, 2019, 10:457.
    [125] UDAYAPPAN S, MANNERAS-HOLM L, CHAPLIN-SCOTT A, BELZER C, HERREMA H, DALLINGA-THIE GM, DUNCAN SH, STROES ESG, GROEN AK, FLINT HJ, BACKHED F, de VOS WM, NIEUWDORP M. Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice[J]. Npj Biofilms and Microbiomes, 2016, 2:16009.
    [126] GÓMEZ del PULGAR EM, BENÍTEZ-PÁEZ A, SANZ Y. Safety assessment of Bacteroides uniformis CECT 7771, a symbiont of the gut microbiota in infants[J]. Nutrients, 2020, 12(2):551.
    [127] WANG TY, ZHANG XQ, CHEN AL, ZHANG J, LV BH, MA MH, LIAN J, WU YX, ZHOU YT, MA CC, DONG RJ, GE DY, GAO SH, JIANG GJ. A comparative study of microbial community and functions of type 2 diabetes mellitus patients with obesity and healthy people[J]. Applied Microbiology and Biotechnology, 2020, 104(16):7143-7153.
    [128] TAKÁČOVÁ M, BOMBA A, TÓTHOVÁ C, MICHÁĽOVÁ A, TURŇA H. Any future for faecal microbiota transplantation as a novel strategy for gut microbiota modulation in human and veterinary medicine?[J]. Life, 2022, 12(5):723.
    [129] KOZIEŁ K, URBANSKA EM. Kynurenine pathway in diabetes mellitus-novel pharmacological target?[J]. Cells, 2023, 12(3):460.
    [130] PIQUÉ N, BERLANGA M, MIÑANA-GALBIS D. Health benefits of heat-killed (tyndallized) probiotics:an overview[J]. International Journal of Molecular Sciences, 2019, 20(10):2534.
    [131] WARDA AK, de ALMEIDA BETTIO PH, HUESTON CM, Di BENEDETTO G, CLOONEY AG, HILL C. Oral administration of heat-treated lactobacilli modifies the murine microbiome and reduces Citrobacter induced colitis[J]. Frontiers in Microbiology, 2020, 11:69.
    [132] BARAL KC, BAJRACHARYA R, LEE SH, HAN HK. Advancements in the pharmaceutical applications of probiotics:dosage forms and formulation technology[J]. International Journal of Nanomedicine, 2021, 16:7535-7556.
    [133] 高向新, 陈永福, 乌斯嘎勒. 益生菌微胶囊的制备及其在食品中应用的研究进展[J]. 食品工业科技, 2023, 44(3):19-28. GAO XX, CHEN YF, WUSIGALE. Research progress of preparation and application of probiotic microencapsulation in food[J]. Science and Technology of Food Industry, 2023, 44(3):19-28(in Chinese).
    [134] YOHA KS, NIDA S, DUTTA S, MOSES JA, ANANDHARAMAKRISHNAN C. Targeted delivery of probiotics:perspectives on research and commercialization[J]. Probiotics and Antimicrobial Proteins, 2022, 14(1):15-48.
    [135] PAN JZ, GONG GD, WANG Q, SHANG JJ, HE YX, CATANIA C, BIRNBAUM D, LI YF, JIA ZJ, ZHANG YY, JOSHI NS, GUO JL. A single-cell nanocoating of probiotics for enhanced amelioration of antibiotic-associated diarrhea[J]. Nature Communications, 2022, 13:2117.
    [136] AL-ISHAQ RK, SAMUEL SM, BÜSSELBERG D. The influence of gut microbial species on diabetes mellitus[J]. International Journal of Molecular Sciences, 2023, 24(9):8118.
    [137] ROTTNER AK, YE YY, NAVARRO-GUERRERO E, RAJESH V, POLLNER A, BEVACQUA RJ, YANG J, SPIGELMAN AF, BARONIO R, BAUTISTA A, THOMSEN SK, LYON J, NAWAZ S, SMITH N, WESOLOWSKA-ANDERSEN A, FOX JEM, SUN H, KIM SK, EBNER D, MACDONALD PE, et al. A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of beta cell function influencing type 2 diabetes risk[J]. Nature Genetics, 2023, 55(1):54-65.
    [138] SINGH RP, SHADAN A, MA Y. Biotechnological applications of probiotics:a multifarious weapon to disease and metabolic abnormality[J]. Probiotics and Antimicrobial Proteins, 2022, 14(6):1184-1210.
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

李永振,张甜甜,王俊贤,张冠军,徐海燕,邵庆武,谷巍. 益生菌在血糖调控中的作用[J]. 微生物学通报, 2024, 51(1): 17-35

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2023-06-26
  • 录用日期:2023-08-30
  • 在线发布日期: 2024-01-02
  • 出版日期: 2024-01-20
文章二维码